Spyre Therapeutics, Inc. (SYRE) shares surged 25.07 percent to $64.15, gaining $12.86 on Monday, after the company reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial evaluating SPY001 for ulcerative colitis.
The stock is currently trading at $64.15, up sharply from its previous close of $51.29 on the Nasdaq. It opened at $66.50 and has traded in a range of $59.02 to $75.00 during the session, with volume reaching 3.85 million shares compared to an average of 747,248 shares.
The company said SPY001 demonstrated promising efficacy and safety, supporting its potential as a best-in-class anti-a4ß7 therapy. Enrollment for Part A has been completed, with Part B now underway, and additional data from other cohorts expected through 2026 and 2027.
The 52-week range for the stock is $12.04 to $75.00.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.